Cargando...
Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States
INTRODUCTION: Eculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk. In the United States, meningococcal vaccines are recommended for eculizumab recipients but there are no...
Gardado en:
| Publicado en: | PLoS One |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Public Library of Science
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7660549/ https://ncbi.nlm.nih.gov/pubmed/33180804 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0241989 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|